# Retatrutide: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on retatrutide (LY3437943) — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist with the largest pharmacologic weight loss reported to date, graded A on human Phase 3 RCTs, but FDA-unapproved and WADA-prohibited as of mid-2026.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Retatrutide (LY3437943) is Eli Lilly's investigational once-weekly **triple agonist** — a single peptide that activates the GIP, GLP-1 and glucagon receptors at once. Its weight-loss and glycemic data are genuinely **Grade A**, resting on human randomized controlled trials including Phase 3 (TRIUMPH-1, TRIUMPH-4). But as of mid-2026 it is **not FDA-approved, not legally compoundable, and prohibited in sport at all times** — the only legitimate human exposure is a clinical trial.[1](https://peptidevox.com/#r1)[14](https://peptidevox.com/#r14)

Retatrutide is, on the evidence, the most potent investigational metabolic agent studied to date — adding glucagon-driven energy expenditure and hepatic lipid mobilization to the dual-incretin mechanism of tirzepatide.[1](https://peptidevox.com/#r1) The headlines are spectacular and, unusually for a popular peptide, largely earned in humans. This monograph separates what is proven from what is premature.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Retatrutide is an investigational drug that is not approved by the FDA or any other regulator; the only lawful human exposure is within a registered clinical trial. Doses are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is retatrutide and how does it work?

Retatrutide (development code LY3437943) is a synthetic, single-molecule peptide conjugated to a fatty diacid (C20) lipid moiety that prolongs circulation by promoting albumin binding — the same lipidation strategy used in modern incretin agonists.[1](https://peptidevox.com/#r1) It is engineered to act as an agonist at three distinct receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor.[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3)

In cell-based assays the potency is deliberately imbalanced across its three targets. Relative to the native ligands, retatrutide is roughly 2.9-fold less potent at the glucagon receptor and 2.5-fold less potent at the GLP-1 receptor, but approximately 8.9-fold more potent at the human GIP receptor.[3](https://peptidevox.com/#r3) The GLP-1 and GIP arms drive satiety, slowed gastric emptying and glucose-dependent insulin secretion; the glucagon-receptor arm is the novel addition, increasing energy expenditure and stimulating hepatic fat oxidation and lipolysis — the proposed driver of both the larger weight loss versus dual agonists and the dramatic liver-fat reductions.[4](https://peptidevox.com/#r4) From a functional, root-cause perspective the glucagon component is what distinguishes retatrutide: rather than relying on appetite suppression alone, it is built to mobilize and oxidize stored hepatic and visceral lipid — though that same arm mandates careful attention to glucose, heart rate and ketone signals.

Pharmacokinetically the drug shows approximately dose-proportional behavior and a half-life of about 6 days, which supports once-weekly subcutaneous dosing.[1](https://peptidevox.com/#r1) As a lipidated peptide it is not orally bioavailable in this form. Weight and liver-fat reductions are dose-dependent and, in the Phase 2 obesity trial, had not plateaued by 48 weeks; heart rate rose dose-dependently, peaking around 24 weeks and declining thereafter.[1](https://peptidevox.com/#r1)

## What is the evidence by indication?

Unlike most peptides covered in this encyclopedia, retatrutide's leading indications rest on human randomized controlled trials, including Phase 3 — so the highest grade is A, not C. The table summarizes the evidence; the registry record for the ongoing Phase 3 diabetes basket is at [ClinicalTrials.gov (NCT05929079)](https://clinicaltrials.gov/study/NCT05929079).[16](https://peptidevox.com/#r16)

  Retatrutide evidence by indication

    IndicationBest evidenceGrade

    Obesity / weight lossPhase 2 NEJM (~24% at 48 wks) + Phase 3 TRIUMPH-1 (~28-30% at 80-104 wks)A
    Type 2 diabetes glycemic controlPhase 2 Lancet (HbA1c -2.0%) + Phase 3 TRANSCEND-T2D-1A
    Obesity-related knee osteoarthritis painOne Phase 3 RCT (TRIUMPH-4, topline)A/B
    MASLD / MASH (liver fat)Single Phase 2a RCT (Nature Medicine; ~80-86% relative reduction)B
    OSA, chronic low-back pain, cardiorenalPhase 3 trials ongoing; no efficacy readouts gradedPending

**Obesity (Grade A).** The 48-week Phase 2 trial (NCT04881760) enrolled 338 adults and reported least-squares mean weight change at 48 weeks of -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg) and -24.2% (12 mg) versus -2.1% with placebo; at 48 weeks the 12 mg group reached 100% (at least 5%), 93% (at least 10%) and 83% (at least 15%) responder rates, with curves still climbing.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) The pivotal 80-week Phase 3 TRIUMPH-1 trial (NCT05929066) randomized 2,339 adults and reported mean reductions of 19.0% (4 mg), 25.9% (9 mg) and 28.3% (12 mg) versus 2.2% placebo; at 12 mg, 62.5% achieved at least 25%, 45.3% at least 30% and 27.2% at least 35% weight loss, and high-BMI participants continued to 104 weeks lost about 30.3% — approaching bariatric-surgery territory.[8](https://peptidevox.com/#r8)[9](https://peptidevox.com/#r9) This exceeds the ~15% (semaglutide) and ~20% (tirzepatide) benchmarks.[13](https://peptidevox.com/#r13) TRIUMPH-1 is reported as a sponsor topline with the full manuscript pending — graded A on RCT design with that caveat.

**Type 2 diabetes (Grade A).** The 36-week Phase 2 Lancet trial enrolled 281 adults with T2D and, at the 24-week primary endpoint, lowered HbA1c by -1.39% (4 mg), -1.99% (8 mg slow escalation) and -2.02% (12 mg) versus -0.01% placebo and -1.41% for the dulaglutide comparator, with the higher arms superior to dulaglutide and no severe hypoglycemia; body weight fell up to ~17% at 36 weeks.[3](https://peptidevox.com/#r3)[12](https://peptidevox.com/#r12) A Phase 3 diabetes trial (TRANSCEND-T2D-1) has been published in The Lancet, extending the glycemic evidence to Phase 3.[5](https://peptidevox.com/#r5)

**Liver fat (Grade B).** A prespecified Phase 2a substudy in 98 participants with MASLD reported relative liver-fat reductions of -42.9% to -82.4% across doses at 24 weeks (versus +0.3% placebo), reaching -86.0% at 12 mg by 48 weeks, with normal liver fat (under 5%) achieved by 89-93% of the high-dose groups and no hepatotoxicity signal.[4](https://peptidevox.com/#r4) This is a single, modestly sized Phase 2a RCT, hence Grade B; a dedicated Phase 3 MASLD/MASH readout is expected.

**Knee osteoarthritis pain (Grade A/B).** The 68-week Phase 3 TRIUMPH-4 trial (NCT05869903) in 445 adults with obesity plus knee osteoarthritis met both co-primary endpoints: weight loss of -26.4% (9 mg) and -28.7% (12 mg), and WOMAC pain reduction of -75.8% / -74.3% versus -40.3% placebo.[6](https://peptidevox.com/#r6)[11](https://peptidevox.com/#r11) This is one positive Phase 3 RCT reported as topline, and the pain benefit is plausibly substantially mediated by weight loss rather than a direct joint effect.

Proven vs hyped
Proven in humans: large, durable weight loss and glycemic improvement in Phase 3 RCTs. Premature: any claim that retatrutide is an approved, safe-to-self-administer therapy. The long-term Phase 3 safety database — cardiovascular outcomes, pancreatitis/gallbladder, the dysesthesia signal, ketone elevations and lean-mass effects — is still maturing, with several readouts topline rather than peer-reviewed at this writing.[6](https://peptidevox.com/#r6)[10](https://peptidevox.com/#r10)

## What doses appear in the literature?

Reported strictly as information, not a protocol — there is no approved prescribing information because the drug is investigational. Retatrutide is given by subcutaneous injection once weekly.[1](https://peptidevox.com/#r1) Phase 2 studied maintenance doses of 1, 4, 8 and 12 mg in obesity and 0.5, 4, 8 and 12 mg in type 2 diabetes (with a dulaglutide 1.5 mg comparator); Phase 3 target doses are 4, 9 and 12 mg for obesity and diabetes and 9 and 12 mg for the knee-OA basket.[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3)[6](https://peptidevox.com/#r6) Trials used stepwise dose escalation, commonly starting at 2 mg weekly with increases roughly every 4 weeks to the target dose; a 2 mg start was better tolerated than a 4 mg start and reduced gastrointestinal adverse events.[1](https://peptidevox.com/#r1)[8](https://peptidevox.com/#r8) Clinical-trial material is supplied pre-formulated by the sponsor; lyophilized 'research-chemical' retatrutide requiring buyer reconstitution is unapproved, unverified and outside any legitimate clinical pathway.[14](https://peptidevox.com/#r14)

## How safe is retatrutide?

The dominant adverse events across trials were gastrointestinal and dose-related — nausea, vomiting, diarrhea, constipation and decreased appetite — mostly mild-to-moderate and more frequent at 8-12 mg and with faster escalation; in TRIUMPH-4 the 12 mg rates were nausea 43.2%, diarrhea 33.1%, constipation 25.0% and vomiting 20.9%.[6](https://peptidevox.com/#r6)[1](https://peptidevox.com/#r1) Retatrutide produced dose-dependent heart-rate increases that peaked around 24 weeks and declined by 36-48 weeks, alongside favorable secondary cardiometabolic shifts (lower non-HDL cholesterol, triglycerides, hsCRP and systolic blood pressure).[1](https://peptidevox.com/#r1)[6](https://peptidevox.com/#r6) A relatively retatrutide-specific signal is dysesthesia (abnormal skin sensation), reported in about 20.9% at 12 mg versus 0.7% placebo, generally mild.[6](https://peptidevox.com/#r6) The glucagon arm raised beta-hydroxybutyrate (ketones), which was not associated with ketoacidosis, and no severe hypoglycemia occurred in the diabetes trial.[4](https://peptidevox.com/#r4)[3](https://peptidevox.com/#r3) AE-driven discontinuation in TRIUMPH-4 was 12.2% (9 mg) and 18.2% (12 mg) versus 4.0% placebo, with some discontinuations attributed to perceived excessive weight loss.[6](https://peptidevox.com/#r6)

Because no approved label exists, class-based GLP-1/GIP cautions are reasoned by analogy rather than established for retatrutide: the GLP-1 class label carries a boxed warning for thyroid C-cell tumors (contraindicating use with a personal or family history of medullary thyroid carcinoma or MEN-2), and class-associated risks of pancreatitis, gallbladder disease and possible aspiration during sedation from delayed gastric emptying are monitored across incretin programs.[1](https://peptidevox.com/#r1) Pregnancy and lactation are clear avoids pending data. These are not yet retatrutide-specific findings and require its own Phase 3 safety database to confirm or refute.

## What is the FDA and WADA status in 2026?

Retatrutide is not approved for any indication as of mid-2026; it is an investigational drug under an IND, lawfully administered only within registered clinical trials. The pivotal TRIUMPH-1 obesity topline read out in May 2026 and anchors planned regulatory filings, with sponsor and analyst expectations pointing to potential approval around 2027 to 2028.[8](https://peptidevox.com/#r8)[14](https://peptidevox.com/#r14) It is also not eligible for pharmacy compounding under 503A or 503B — it has no USP/NF monograph, is not a component of an FDA-approved drug, and was not among the peptides reclassified out of FDA Category 2 in April 2026 (that action covered substances like BPC-157 and TB-500, not retatrutide).[14](https://peptidevox.com/#r14) Retatrutide sold online as a 'research chemical' is unapproved, labeled not for human consumption, and not a lawful dietary-supplement ingredient; grey-market peptide samples broadly show high rates of mislabeling and contamination.[15](https://peptidevox.com/#r15)

For athletes the picture is unambiguous. Retatrutide is prohibited at all times: as an unapproved drug it is captured by S0 (non-approved substances), and additionally, as a GLP-1 receptor agonist, it falls under S2.4 (peptide hormones, GLP-1 analogues and receptor agonists).[14](https://peptidevox.com/#r14) 'Research-chemical' labeling provides no anti-doping protection, and incretin peptides can be detected long after use. Any WADA-tested athlete should treat retatrutide as categorically off-limits.

**Bottom line.** Retatrutide pairs the strongest human efficacy data of any peptide in this encyclopedia — Grade A weight-loss and glycemic results across Phase 2 and Phase 3 RCTs, with the glucagon arm as the real mechanistic differentiator — with the plain reality that it is not yet an approved or lawful therapy. As of mid-2026 it is investigational, not legally compoundable, not a lawful supplement and WADA-prohibited at all times; the only legitimate human exposure is a clinical trial, and online product is unapproved and frequently adulterated. A transformative-looking drug awaiting regulatory approval and the maturation of its long-term safety record — not a peptide to source or self-use. Regulatory and topline-trial facts here are current as of June 2026 and should be re-verified as the full Phase 3 manuscripts and any FDA decisions publish.

---
Source: https://peptidevox.com/peptide-encyclopedia/retatrutide
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt